CXCL12 and B-cell chronic lymphocytic leukemia: Altogether, our data identify JAK2 as a critical regulator of B-lymphocyte adhesion by CXCL12 and suggest that inhibition of JAK2 could be an innovative therapeutic approach to B-CLL treatment.